Literature DB >> 8425646

Adverse effects of leuprolide acetate depot treatment.

A J Friedman1, M Juneau-Norcross, M S Rein.   

Abstract

One hundred two premenopausal women with uterine myomas were treated with LA depot. All women experienced adverse effects during GnRH-a treatment. The majority experienced symptoms attributed to a rapid and sustained decrease in circulating estrogen concentrations beginning 2 to 7 weeks after initiation of treatment. A smaller percentage of women experienced transient adverse effects due to the initial surge and subsequent rapid decline of gonadal steroids. The mechanism of other adverse effects (e.g., arthralgias) remains unclear. Only 6% of women terminated LA treatment before 12 weeks because of the severity of adverse effects.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8425646     DOI： 10.1016/s0015-0282(16)55701-x

Source DB:  PubMed          Journal:  Fertil Steril        ISSN： 0015-0282            Impact factor:   7.329


  9 in total

1.  Toxic hepatitis after sequential administration of flutamide and cyproterone acetate.

Authors:  Spilios Manolakopoulos; Sotirios Bethanis; Anastasios Armonis; Michalis Economou; Alec Avgerinos; Dimitrios Tzourmakliotis
Journal:  Dig Dis Sci       Date:  2004-03       Impact factor: 3.199

2.  Effects of surgical and chemical castration on spatial learning ability in relation to cell proliferation and apoptosis in hippocampus.

Authors:  Mal-Soon Shin; Kyung Jin Chung; Il-Gyu Ko; Sang-Hoon Kim; Jun-Jang Jin; Sung-Eun Kim; Jae-Min Lee; Eun-Sang Ji; Tae-Woon Kim; Han-Sam Cho; Chang Hee Kim; Young-Sam Cho; Chang-Ju Kim; Khae-Hawn Kim
Journal:  Int Urol Nephrol       Date:  2016-01-18       Impact factor: 2.370

3.  Vitamin D receptor and enzyme expression in dorsal root ganglia of adult female rats: modulation by ovarian hormones.

Authors:  Sarah E Tague; Peter G Smith
Journal:  J Chem Neuroanat       Date:  2010-10-20       Impact factor: 3.052

4.  Flutamide-induced toxic hepatitis. Potential utility of ursodeoxycholic acid administration in toxic hepatitis.

Authors:  C Cicognani; M Malavolti; A M Morselli-Labate; C Sama; L Barbara
Journal:  Dig Dis Sci       Date:  1996-11       Impact factor: 3.199

5.  Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors.

Authors:  N Lynn Henry; Jon T Giles; Dennis Ang; Monika Mohan; Dina Dadabhoy; Jason Robarge; Jill Hayden; Suzanne Lemler; Karineh Shahverdi; Penny Powers; Lang Li; David Flockhart; Vered Stearns; Daniel F Hayes; Anna Maria Storniolo; Daniel J Clauw
Journal:  Breast Cancer Res Treat       Date:  2007-10-06       Impact factor: 4.872

6.  Bone loss during gonadotropin releasing hormone agonist treatment and use of nasal calcitonin.

Authors:  C Roux; C Pelissier; V Listrat; S Kolta; C Simonetta; M Guignard; M Dougados; B Amor
Journal:  Osteoporos Int       Date:  1995-05       Impact factor: 4.507

Review 7.  Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.

Authors:  G L Plosker; R N Brogden
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

Review 8.  Gonadotrophin-releasing hormone agonists. A guide to use and selection.

Authors:  M Filicori
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

Review 9.  Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management.

Authors:  Stéphanie Gaillard; Vered Stearns
Journal:  Breast Cancer Res       Date:  2011-03-14       Impact factor: 6.466
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.